Skip to main content
. Author manuscript; available in PMC: 2020 Nov 19.
Published in final edited form as: J Med Chem. 2019 Apr 19;62(9):4444–4455. doi: 10.1021/acs.jmedchem.8b01943

Figure 7.

Figure 7.

Potency (IC50 values) for compounds with various substitutions at the P1′site against proteasome chymotrypsin-like activity (RPMI8226 cell lysate), β1i/LMP2 activity (purified human 20S immunoproteasome), and cell viability of H23, H727, and Cfz-resistant RPMI8226 cells. Data reported as the mean ± SD (carfilzomib, n = 3 independent experiments) or from a single experiment (3 replicates, 7, 9, and 12).